www.asiabiotech.com Industry Watch

China

Sinovac Biotech to Increase Stake in Subsidiary

hinese biopharma major Sinovac Biotech said China Bioway Biotech Group, a 28.44 percent minority shareholder in its 71.56 percent PRC subsidiary, Sinovac CChina, has recently received approvals from the PRC Ministry of Education and the PRC Ministry of Commerce to restructure China Bioway’s equity interest in Sinovac China. Sinovac Biotech is exploring with China Bioway the possibility of the company’s acquisition of China Bioway’s minority interest in Sinovac China. However, Sinovac has not commenced any formal negotiation or entered into any definitive agreement with China Bioway. Sinovac China has recently received approvals from the PRC Ministry of Education and the PRC Ministry of Commerce to restructure China Bioway’s equity interest in Sinovac China.

About Sinovac Biotech Ltd Sinovac Biotech Ltd. specializes in the research, development, and commercialization of human for infectious diseases such as Hepatitis A and Hepatitis B, , “SARS”, avian influenza, etc. Sinovac is one of the leading emerging biotechnology companies in China. Working closely with Chinese public health officials, Sinovac focuses on manufacturing and marketing human-use vaccines and related products, and currently markets its Hepatitis A and Hepatitis A&B vaccine. Sinovac is the first company in the world to have been granted permission to conduct clinical trials for a vaccine to prevent SARS. It is the only company that has completed phase I clinical trial on SARS vaccine.

Contact Details: Sinovac Biotech Ltd Address: 39 Shangdi Xi Road, Haidian District, 100085 Tel: +86 108 289 0088 Fax: +86 106 296 6910 URL: www.sinovac.com

APBN • Vol. 11 • No. 3 • 2007 161